Rizatriptan
- Generic Name
- Rizatriptan
- Brand Names
- Maxalt, Rizaport
- Drug Type
- Small Molecule
- Chemical Formula
- C15H19N5
- CAS Number
- 144034-80-0
- Unique Ingredient Identifier
- 51086HBW8G
Overview
Rizatriptan is a second-generation triptan and a selective 5-HT receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations.
Background
Rizatriptan is a second-generation triptan and a selective 5-HT receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations.
Indication
Rizatriptan is indicated for the acute treatment of diagnosed migraine with or without aura. Rizatriptan is not indicated for the prophylactic therapy of migraine nor the treatment of cluster headache. In Canada, rizatriptan is approved in adults. In the US, the oral tablet formulations are used in patients six years of age and older and the oral film formation is approved for patients 12 years of age and older weighing 40 kg or more.
Associated Conditions
- Migraine With Aura
- Migraine Without Aura
- Migraine with acute onset aura
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.